ALNY
NASDAQHealthcareLoading…
Alnylam Pharmaceuticals, Inc. - Common Stock
Sector: Healthcare•United States•Market Cap: $43.6B
Related News
Latest stories connected to ALNY
- RS 53Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise TranscriptSeeking Alpha•Mar 24, 2026•Original source
- RS 53Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart AssociationBusiness Wire•Mar 24, 2026•Original source
- RS 53Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?Zacks Investment Research•Mar 19, 2026•Original source
- RS 53Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Financial Performance and Industry ComparisonFinancial Modeling Prep•Mar 3, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | 3.71B | 2.25B | 1.83B | 1.04B | 844.29M | 492.85M | 219.75M | 74.91M | 89.91M | 47.16M |
| Cost of Revenue | 677.17M | 323.37M | 310.41M | 168.82M | 140.14M | 78.05M | 25.06M | 1.80M | 13.37M | 0 |
| Gross Profit | 3.04B | 1.92B | 1.52B | 868.60M | 704.14M | 414.80M | 194.69M | 73.11M | 76.55M | 47.16M |
| Research and Development Expenses | 1.32B | 1.13B | 1.00B | 883.01M | 792.16M | 654.82M | 655.11M | 505.42M | 390.63M | 382.39M |
| General and Administrative Expenses | 0 | 975.53M | 795.65M | 770.66M | 620.64M | 588.42M | 479.00M | 382.36M | 199.37M | 89.35M |
| Selling and Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General and Administrative Expenses | 1.21B | 975.53M | 795.65M | 770.66M | 620.64M | 588.42M | 479.00M | 382.36M | 199.37M | 89.35M |
| Other Expenses | 0 | 0 | 0 | 0 | -2.05M | 0 | 0 | 4.17M | -3.02M | 0 |
| Operating Expenses | 2.54B | 2.10B | 1.80B | 1.65B | 1.41B | 1.24B | 1.13B | 887.78M | 590.00M | 471.75M |
| Cost and Expenses | 3.21B | 2.43B | 2.11B | 1.82B | 1.55B | 1.32B | 1.16B | 889.58M | 590.00M | 471.75M |
| Net Interest Income | -141.16M | -19.87M | -25.66M | -131.16M | -141.44M | -72.69M | 33.45M | 29.26M | 12.24M | 8.31M |
| Interest Income | 111.47M | 121.99M | 95.56M | 24.81M | 1.58M | 11.81M | 33.45M | 29.26M | 12.24M | 8.31M |
| Interest Expense | 252.63M | 141.86M | 121.22M | 155.97M | 143.02M | 84.50M | 0 | 0 | 0 | 0 |
| Depreciation and Amortization | 55.66M | 56.67M | 97.03M | 85.55M | 89.69M | 74.44M | 54.37M | 6.43M | 13.37M | 15.13M |
| EBITDA | 557.24M | -178.85M | -258.24M | -926.56M | -661.56M | -736.33M | -868.08M | -754.24M | -488.19M | -409.46M |
| EBIT | 501.58M | -235.52M | -312.30M | -971.02M | -709.12M | -771.10M | -885.25M | -760.67M | -500.09M | -424.59M |
| Non Operating Income Excluding Interest | 0 | 58.63M | 30.12M | 185.95M | 471.00K | -57.33M | -54.18M | -54.00M | 0 | 0 |
| Operating Income | 501.58M | -176.88M | -282.18M | -785.07M | -708.65M | -828.44M | -939.43M | -814.67M | -500.09M | -424.59M |
| Total Other Income Expenses Net | -178.43M | -200.49M | -151.34M | -341.92M | -143.49M | -27.16M | 54.18M | 54.00M | 9.21M | 14.48M |
| Income Before Tax | 323.15M | -377.38M | -433.52M | -1.13B | -852.14M | -855.60M | -885.25M | -760.67M | -490.87M | -410.11M |
| Income Tax Expense | 9.40M | -99.22M | 6.72M | 4.16M | 680.00K | 2.68M | 863.00K | 823.00K | 0 | 0 |
| Net Income From Continuing Operations | 313.75M | -278.16M | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.50M | -490.87M | -410.11M |
| Net Income From Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 313.75M | -278.16M | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.50M | -490.87M | -410.11M |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | 2.39 | -2.18 | -3.52 | -9.3 | -7.2 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 |
| EPS Diluted | 2.33 | -2.18 | -3.52 | -9.3 | -7.2 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 |
| Weighted Average SHS Out | 131.00M | 127.65M | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M |
| Weighted Average SHS Out Dil | 134.68M | 127.65M | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.82 | 0.86 | 0.83 | 0.84 | 0.83 | 0.84 | 0.89 | 0.98 | 0.85 | 1 |
| R&D to Revenue | 0.36 | 0.5 | 0.55 | 0.85 | 0.94 | 1.33 | 2.98 | 6.75 | 4.34 | 8.11 |
| SG&A to Revenue | 0 | 0.43 | 0.44 | 0.74 | 0.74 | 1.19 | 2.18 | 5.1 | 2.22 | 1.89 |
| Interest Burden | 0.64 | 1.6 | 1.39 | 1.16 | 1.2 | 1.11 | 1 | 1 | 0.98 | 0.97 |
| EBIT Margin | 0.14 | -0.1 | -0.17 | -0.94 | -0.84 | -1.56 | -4.03 | -10.15 | -5.56 | -9 |
| EBITDA Margin | 0.15 | -0.08 | -0.14 | -0.89 | -0.78 | -1.49 | -3.95 | -10.07 | -5.43 | -8.68 |
| EBT per EBIT | 0.64 | 2.13 | 1.54 | 1.44 | 1.2 | 1.03 | 0.94 | 0.93 | 0.98 | 0.97 |
| Effective Tax Rate | 0.03 | 0.26 | -0.02 | -0 | -0 | -0 | -0 | -0 | 0 | 0 |
| Tax Burden | 0.97 | 0.74 | 1.02 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Cont. Operations Profit Margin | 0.08 | -0.12 | -0.24 | -1.09 | -1.01 | -1.74 | -4.03 | -10.17 | -5.46 | -8.7 |
| Bottom Line Profit Margin | 0.08 | -0.12 | -0.24 | -1.09 | -1.01 | -1.74 | -4.03 | -10.17 | -5.46 | -8.7 |
| Operating Cycle | 121 | 154.42 | 170.26 | 362.55 | 310.78 | 797.81 | 892.09 | 4.97K | 138.03 | 180.6 |
| Fwd PEG Ratio | -0.79 | 2.84 | 0.87 | -0.88 | 6.76 | 2.17 | -1.99 | -0.24 | -1.78 | -0.2 |
| Earnings Yield | 0.01 | -0.01 | -0.02 | -0.04 | -0.04 | -0.06 | -0.07 | -0.1 | -0.04 | -0.13 |
| Income Quality | 1.67 | 0.03 | -0.24 | 0.48 | 0.75 | 0.72 | 0.31 | 0.74 | 0.78 | 0.75 |